John Weiser

John Weiser

Auto-generated profile, based on publicly available information

John Weiser

Margaret A. Lampe, RN, MPH, is an Epidemiologist in the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention at the Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
JWJohn Weiser
John Weiser
LBLinda Beer
Linda Beer
EFEmma L. Frazier
Emma L. Frazier
RPRoshni Patel
Roshni Patel
ADAntigone Dempsey
Antigone Dempsey
JSJacek Skarbinski
Jacek Skarbinski
The Ryan White Human Immunodeficiency Virus (HIV)/AIDS Program (RWHAP) was established in 1990 to provide funds to states, eligible metropolitan areas, and clinics to increase access to high-quality HIV care and treatment for low-income, uninsured, and underinsured individuals and families affected by HIV infection.1 An estimated 873 000 persons were living with a diagnosis of HIV infection in the United States at the end of 2010.2 The RWHAP reaches more than 500 000 people annually3 and accounts for 16% of federal spending on HIV care and treatment.4 Administered by the Health Resources and Services Administration, the RWHAP provides funding as a payer of last resort for core medical services, including outpatient medical care, medications for the treatment of HIV disease, medical case management, and antiretroviral therapy (ART) adherence support. In addition, HIV care facilities receive RWHAP funding to provide comprehensive support services, including nonmedical case management; assistance with food, housing, and transportation; mental health and substance abuse services; and HIV transmission risk reduction counseling.

29 June 2016 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JWJohn Weiser
John Weiser
LBLinda Beer
Linda Beer
BWBrady T. West
Brady T. West
CDChristopher C. Duke
Christopher C. Duke
GGGarrett W. Gremel
Garrett W. Gremel
JSJacek Skarbinski
Jacek Skarbinski
Background. The human immunodeficiency virus (HIV)–infected population in the United States is increasing by about 30 000 annually (new infections minus deaths). With improvements in diagnosis and engagement in care, additional qualified HIV care providers may be needed. Methods. We surveyed a probability sample of 2023 US HIV care providers in 2013–2014, including those at Ryan White HIV/AIDS Program (RWHAP)–funded facilities and in private practices. We estimated future patient care capacity by comparing counts of providers entering and planning to leave practice within 5 years, and the number of patients under their care. Results. Of surveyed providers, 1234 responded (adjusted response rate, 64%): 63% were white, 11% black, 11% Hispanic, and 16% other race/ethnicity; 37% were satisfied/very satisfied with salary/reimbursement, and 33% were satisfied/very satisfied with administrative time. Compared with providers in private practice, more providers at RWHAP-funded facilities were HIV specialists (71% vs 43%; P < .0001) and planned to leave HIV practice within 5 years (11% vs 4%; P = .0004). An estimated 190 more full-time equivalent providers (defined as 40 HIV clinical care hours per week) entered practice in the past 5 years than are expected to leave in the next 5 years. If these rates continue, by 2019 patient care capacity will increase by 65 000, compared with an increased requirement of at least 100 000. Conclusions. Projected workforce growth by 2019 will not accommodate the increased number of HIV-infected persons requiring care. RWHAP-funded facilities may face attrition of highly qualified providers. Dissatisfaction with salary/reimbursement and administrative burden is substantial, and black and Hispanic providers are underrepresented relative to HIV patients.

17 December 2020 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
JWJohn K. Weiser
John K. Weiser
YTYunfeng Tie
Yunfeng Tie
LBLinda Beer
Linda Beer
RFRobyn Neblett Fanfair
Robyn Neblett Fanfair
RSRoy Luke Shouse
Roy Luke Shouse
Background: Health inequities among people with HIV may be compounded by disparities in the prevalence of comorbidities associated with an increased risk of severe illness from COVID-19. Setting: Complex sample survey designed to produce nationally representative estimates of behavioral and clinical characteristics of adults with diagnosed HIV in the United States. Methods: We estimated the prevalence of having ≥1 diagnosed comorbidity associated with severe illness from COVID-19 and prevalence differences (PDs) by race/ethnicity, income level, and type of health insurance. We considered PDs ≥5 percentage points to be meaningful from a public health perspective. Results: An estimated 37.9% [95% confidence interval (CI): 36.6 to 39.2] of adults receiving HIV care had ≥1 diagnosed comorbidity associated with severe illness from COVID-19. Compared with non-Hispanic Whites, non-Hispanic Blacks or African Americans were more likely [adjusted PD, 7.8 percentage points (95% CI: 5.7 to 10.0)] and non-Hispanic Asians were less likely [adjusted PD, −13.7 percentage points (95% CI: −22.3 to −5.0)] to have ≥1 diagnosed comorbidity after adjusting for age differences. There were no meaningful differences between non-Hispanic Whites and adults in other racial/ethnic groups. Those with low income were more likely to have ≥1 diagnosed comorbidity [PD, 7.3 percentage points (95% CI: 5.1 to 9.4)]. Conclusions: Among adults receiving HIV care, non-Hispanic Blacks and those with low income were more likely to have ≥1 diagnosed comorbidity associated with severe COVID-19. Building health equity among people with HIV during the COVID-19 pandemic may require reducing the impact of comorbidities in heavily affected communities.

12 November 2014 in Journal of the International Association of Providers of AIDS Care (JIAPAC)
Verified
Journal Article
Open access
LBLinda Beer
Linda Beer
EVEduardo E. Valverde
Eduardo E. Valverde
JRJerris L. Raiford
Jerris L. Raiford
JWJohn Weiser
John Weiser
BWBecky L. White
Becky L. White
JSJacek Skarbinski
Jacek Skarbinski
Objectives: Guidelines for antiretroviral therapy (ART) initiation have evolved, but consistently note that adherence problems should be considered and addressed. Little is known regarding the reasons providers delay ART initiation in clinically eligible patients. Methods: In 2009, we surveyed a probability sample of HIV care providers in 582 outpatient facilities in the United States and Puerto Rico with an open-ended question about nonclinical reasons for delaying ART initiation in otherwise clinically eligible patients. Results: Very few providers (2%) reported never delaying ART. Reasons for delaying ART were concerns about patient adherence (68%), patient acceptance (60%), and structural barriers (33%). Provider and practice characteristics were associated with reasons for delaying ART. Conclusion: Reasons for delaying ART were consistent with clinical guidelines and were both patient level and structural. Providers may benefit from training and access to referrals for ancillary services to enhance their ability to monitor and address these issues with their patients.

20 February 2018 in Annals of Internal Medicine
Verified
Journal Article
Closed access
JWJohn Weiser
John Weiser
APAlejandro Perez
Alejandro Perez
HBHeather Bradley
Heather Bradley
HKHope King
Hope King
RSR. Luke Shouse
R. Luke Shouse
Persons with HIV infection are at increased risk for hepatitis B virus infection. In this study, the authors used a nationally representative cross-sectional survey to estimate the prevalence of he... Background: Persons with HIV infection are at increased risk for hepatitis B virus infection. In 2016, the World Health Organization resolved to eliminate hepatitis B as a public health threat by 2...

27 April 2024 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
SRSun Hee Rim
Sun Hee Rim
LBLinda Beer
Linda Beer
MSMona Saraiya
Mona Saraiya
YTYunfeng Tie
Yunfeng Tie
XYXin Yuan
Xin Yuan
JWJohn Weiser
John Weiser
Background: People with HIV at highest risk of anal cancer include gay, bisexual, and other men who have sex with men and transgender women aged 35 years or older as well as other people with HIV aged 45 years or older. Identifying and treating precancerous lesions can reduce anal cancer incidence in these groups. We assessed the prevalence of anal cytology and access to high-resolution anoscopy among people with HIV overall and in those individuals at highest risk. Methods: Data were obtained from the Centers for Disease Control and Prevention’s Medical Monitoring Project, a population-based survey of people with HIV aged 18 years and older, and a supplemental Medical Monitoring Project facility survey. We report weighted percentages of people with HIV receiving anal cytology during the past 12 months, access to high-resolution anoscopy, and characteristics of HIV care facilities by availability of high-resolution anoscopy. Results: Overall, 4.8% (95% confidence interval [CI] = 3.4% to 6.1%) of people with HIV had undergone anal cytology in the prior 12 months. Only 7.7% (95% CI = 5.1% to 10.6%) of gay, bisexual, and other men who have sex with men as well as transgender women 35 years of age or older and 1.9% (95% CI = 0.9% to 2.9%) of all other people with HIV aged 45 years and older had anal cytology. Prevalence was statistically significantly low among people with HIV with the following characteristics: non-Hispanic or Latino, Black or African American, high school education or less, heterosexual orientation, and living in southern Medical Monitoring Project states. Among people with HIV, 32.8% (95% CI = 28.0% to 37.7%) had no access to high-resolution anoscopy on-site or through referral at their care facility; 22.2% (95% CI = 19.5% to 24.9%) had on-site access; 45.0% (95% CI = 41.5% to 48.5%) had high-resolution anoscopy available through referral. Most facilities that received Ryan White HIV/AIDS Program funding, cared for more than 1000 people with HIV, or provided on-site colposcopy also provided high-resolution anoscopy on-site or through referral. Conclusions: Rates of anal cytology and access to high-resolution anoscopy were low among people with HIV, including those individuals at highest risk of anal cancer. Our data may inform large-scale implementation of anal cancer prevention efforts.